- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sheila Frame: Lessons Learned From Launching Zarxio
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses lessons learned from the launch of the company’s biosimilar filgrastim.
Transcript:
Sandoz was the first to launch a biosimilar—Zarxio—in the United States. What are some of the key lessons learned from that product launch?
You know, for Sandoz it's been 35 years' worth of experience developing and selling biopharmaceuticals and biological products. With Zarxio, because it was the first to be launched through the new FDA process with a true biosimilar, we have learned so much, and we've had such incredible success.
It takes a little while, right, for the marketplace to get used to biosimilars. It was pretty new in the United States. But what we've seen in the last couple of years is just incredible excitement in the marketplace about the value that systems can benefit from and reinvest in patient care. So we've had some terrific successes. We've also had some challenges, as you can imagine, right. I mean, it's new for patients. It's new for treatment providers. So we're really excited that we were able to use Zarxio as the first example. It's something that supports patient care from a managing side effects perspective in oncology. It's relatively speaking a short term therapy.
We're really excited. It has been a tremendous opportunity for many physicians, patients, and other healthcare systems. So we've got some great examples now. We've got good publications behind it. I think people are feeling much more comfortable with the value that biosimilars can bring.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
